TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of orally administered TT-10 in subjects with advanced selected solid tumors. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of TT-10.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tarus Therapeutics, Inc.

Criteria

Inclusion Criteria:

To eligible for inclusion in the dose escalation cohort or expansion cohort 1 in this study, subjects must meet all of the following criteria:

1. Subjects must be ≥18 years of age.

2. Subjects or their legal representative must be able to provide written informed consent to participate in the trial prior to the performance of any study-specific procedures.

3. Diagnosis of histologically or cytologically confirmed advanced selected solid tumors

• Cohort A dose escalation: Renal cell cancer (RCC), castrate resistant prostate cancer (CRPC) and Non-small cell lung cancer (NSCLC) who have failed or are not eligible for standard of care treatment.

• Cohort B: Advanced RCC who have failed or are not eligible for standard of care treatment.

• Cohort C: Advanced CRPC who have failed or are not eligible for standard of care treatment.

• Cohort D: Advanced NSCLC who have failed or are not eligible for standard of care treatment.

• Cohort E: Exploratory Biopsy: Inclusive of subjects w/RCC, CRPC and/or NSCLC who have failed or are not eligible for standard of care treatment and have an accessible tumor for pre and post dose biopsies.

4. ECOG performance status (PS) score 0-1

5. Have measurable disease per RECIST 1.1 or (for subjects in the expansion cohorts) irRECIST as assessed by the local site investigator/radiology. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

6. Subjects must have locally advanced, recurrent or metastatic neoplastic disease that is not curable by currently available local therapies.

7. Failure to respond to standard therapy, or for whom no appropriate therapies are available (based on the judgment of the Investigator)

8. Cohort E Only: Fresh tissue sample obtained prior to treatment initiation and agree to on treatment biopsy from same lesion.

9. Life expectancy of ≥ 3 months

10. Subjects must have adequate hematologic function based on the following:

• Absolute neutrophil count ≥ 1.5 x 109/L

• Platelet count ≥ 100 x 109/L

• Hemoglobin ≥ 9.0 g/dL

11. Subjects must have adequate hepatic function based on the following:

• Total bilirubin <1.5 × upper limit of normal (ULN) (unless elevated due to Gilbert's syndrome)

• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 × ULN for subjects with known hepatic metastases)

12. Subjects must have adequate renal function based on the following:

• Serum creatinine ≤1.5 × ULN; or

• Serum creatinine clearance ≥ 45 mL/min (≥ 30 mL/min for subjects), as determined by Cockcroft-Gault equation

13. Human immunodeficiency virus (HIV) infected subjects must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease defined as:

1. Subjects on ART must have a CD4+ T cell count >350 cells/mm3 at time of screening

2. Subjects on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening

3. Subjects on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).

14. For women of childbearing potential (WCBP): negative urine pregnancy test (UPT) within 1 week before first treatment (WCBP defined as a sexually mature woman who has not undergone surgical sterilization or who has not been naturally post-menopausal for at least 12 consecutive months for women > 55 years of age). WCBP should be placed on effective birth control directly after testing negative for pregnancy; if not, then WCBP should have a UPT on Day 1 of every cycle, prior to drug administration. Any positive or indeterminant UPT result must be confirmed by Serum.

15. Female subjects of childbearing potential must use a highly effective mode of contraception or abstain from heterosexual activity for the duration of the trial and for 120 days following the last dose of study medication. A female is NOT of childbearing potential if she has undergone bilateral salpingoophorectomy or is menopausal, defined as an absence of menses for 12 consecutive months. Male subjects must agree to use highly effective contraception.

16. Ability to adhere to the study visit schedule and all protocol requirements

Exclusion Criteria:

Subjects will be excluded from the study if they satisfy any of the following criteria at the screening visit unless otherwise stated:

Subjects are to be excluded from the study if they meet any of the following criteria:

1. Major surgery within 4 weeks prior to Screening

2. Subjects with active central nervous system (CNS) metastases; however, subjects who have undergone radiation and/or surgery for the treatment of CNS metastases, who are neurologically stable, and who are no longer taking pharmacologic doses of corticosteroids are eligible; subjects with leptomeningeal metastases are not eligible.

3. Has received prior radiotherapy within 2 weeks of start of study treatment. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.

4. Primary CNS malignancy

5. HIV-infected subjects with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.

6. Subjects who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to enrollment.

Note: Subjects should remain on antiviral therapy throughout study intervention and follow local guidelines for HBV antiviral therapy post completion of study intervention.

Hepatitis B screening tests are not required unless:

• Known history of HBV infection

• As mandated by local health authority.

7. Subjects with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. Note: Subjects must have completed curative antiviral therapy at least 4 weeks prior to enrollment.

Hepatitis C screening tests are not required unless:

• Known history of HCV infection

• As mandated by local health authority.

8. Subjects who require immunosuppressive therapy including, but not limited to, treatment with corticosteroids in pharmacologic doses (equivalent to ≥10 mg prednisone daily), cyclosporine, mycophenolate, azathioprine, methotrexate, adalimumab, infliximab, vedolizumab, tofacitinib, dupilumab, rituximab, etc. or systemic steroids (except for steroid use as cortisol replacement therapy in documented adrenal insufficiency)

9. Ongoing systemic bacterial, fungal, or viral infections at Screening

a. NOTE: Subjects on antimicrobial, antifungal, or antiviral prophylaxis are not specifically excluded if all other inclusion/exclusion criteria are met

10. Administration of a live vaccine within 6 weeks of first dose of study drug

11. Baseline QT interval corrected with Fridericia's method (QTcF) > 480 ms (average of triplicate readings)

a. NOTE: Criterion does not apply to subjects with a right or left bundle branch block.

12. Prior surgery or gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypass surgery, gastrectomy)

13. Female subjects who are pregnant or breastfeeding

14. Concurrent active malignancy other than non-melanoma skin cancer, carcinoma in situ of the cervix, or prostate intraepithelial neoplasia

15. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease

16. History of peptic ulcer and/or gastrointestinal bleed within the past 6 months prior to Screening

17. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to Screening

18. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the subject associated with his or her participation in the study.